NCIRS Seminar Series

NCIRS Seminar Series 2017 #6 - Wednesday 27th September 11am-12pm
Addressing vaccine hesitancy and refusal

A/Prof Julie Leask – University of Sydney

Addressing vaccine hesitancy and refusal can be difficult. Online environments produce adversarial discussions about vaccination, intensifying polarisation and marginalising the hesitant. Parents often bring questions or concerns about vaccination to the clinical encounter. How health professionals invite and address these concerns can move parents towards, or further away from, vaccination. Many health professionals find resolute vaccine refusal very challenging.

This seminar will focus on work to support conversations between parents and health professionals called SKAI (Sharing Knowledge About Immunisation). Developed by a multidisciplinary team, SKAI offers communication strategies and resources for three possible pathways aligned to whether parents are (1) ready to vaccinate, (2) hesitant or (3) declining vaccination. The presentation by Julie Leask will focus on findings from early testing in parent focus groups; in-depth interviews with GPs and nurses; and conversations between clinicians and vaccine-hesitant or declining parents. Professor Leask will also present on the broader evidence base of how to improve vaccination coverage, concluding that there is no single formula but that a range of strategies are needed.

Time: Wednesday 27th September 11am-12pm
Location: Seminar Room 1 and 2, CMRI Building, 214 Hawkesbury Road, Westmead, NSW

Register here (for catering please)

Julie Leask is a social scientist and associate professor in the Sydney Nursing School at the University of Sydney. She is also a visiting senior research fellow at the National Centre for Immunisation Research and Surveillance. Julie has academic qualifications in nursing and midwifery, a Master of Public Health (USYD, 1998) and PhD on vaccine risk communication (USYD, 2002). She currently leads a program of research on vaccination acceptance with a focus on primary care and community settings. She has had advisory roles with the WHO Europe Regional Office, the US President’s Cancer Panel, US Institute of Medicine, US National Vaccine Program Office, the Australian Academy of Science, the Council of the National Health and Medical Research Council. In 2015 she won the PHAA NSW branch Public Health Impact Award and the Sax Institute Research Action Award.


NCIRS Seminar Series 2017 #5 - Wednesday 23rd August 2017
Varicella Zoster Virus Vaccines: Preventing Chicken Pox & Shingles

At this seminar we heard from two Varicella Zoster Virus international experts.
A/Prof Kristine Macartney (Deputy Director, NCIRS) provided an overview of the impact of varicella vaccination in Australia, and the introduction of the live-attenuated Zoster vaccine, and Prof Tony Cunningham, AO (Executive Director, WIMR) spoke on the clinical development and potential impact of the new non-live, adjuvanted, subunit (HZ/su) vaccine, Shingrix.

Video resources

1. Talk 1: Varicella and Zoster vaccination Australian update by A/Prof Kristine Macartney


2. Talk 2: The new Herpes zoster vaccine by Prof Tony Cunningham

 3. Questions & Discussion: Varicella Zoster Virus Vaccines: Preventing Chicken Pox & Shingles


NCIRS Seminar Series 2017 #4 - Wednesday 26th July 2017
Tuberculosis & the Bacille Calmette-Guérin (BCG) vaccine: global burden and Australian immunisation programs

In this seminar held on Wednesday 26th July we heard from Professor Ben Marais on global TB disease burden issues and Dr Frank Beard on the BCG vaccine and evaluation of Australian immunisation programs.

Video resources

1. Talk 1: Tuberculosis in children by Professor Ben Marais

 2. Talk 2: The Bacille Calmette-Guérin (BCG) vaccine & Australian immunisation programs by Dr Frank Beard



NCIRS Seminar Series 2017 #3 - Wednesday 24th May
Maternal Immunisation against Pertussis: Latest evidence

Maternal vaccination in the third trimester of pregnancy is now the preferred strategy for protection of infants in the “immunity gap” between birth and three-months of age. This strategy was however implemented in the absence of evidence from clinical trials, and many questions about the details of its effects remain.  

In this seminar Prof. Peter McIntyre (Director, NCIRS) gave an overview of the background on maternal immunisation against pertussis and present some recent evidence from the UK and California. Dr Nathan Saul (Epidemiologist, Vaccine Preventable Diseases at NSW Health) presented breaking data on effectiveness from a NSW case-control study conducted by all public health units in 2015-16.

Video resources

1. Talk 1: Maternal immunisation against pertussis – background and current evidence by Prof Peter McIntyre, NCIRS

 2. The presentation given by Dr Nathan Saul will be made available once the data presented is published - Coming soon


NCIRS Seminar Series 2017 #2 - Wednesday 22 March
All Creatures Great and Small: A One Health Approach to the Problem of Q Fever

Q fever, caused by Coxiella burnetii, is a serious zoonotic disease in humans with a worldwide distribution. Many species of animals are capable of transmitting C. burnetii, and consequently all veterinary workers are at risk for this disease. Australia is the only country to have a licensed Q fever vaccine (QVax ). This vaccine has been readily available and used in Australia for many years in at-risk groups, however still has 600 notifications across Australia annually.

This presentation provided an overview of the sources of Q fever in our animal populations, new data on longevity of immunity post vaccination, as well as information on the safety of the Q fever vaccine in young adults and barriers to uptake of the vaccine.


NCIRS Seminar Series 2017 #1 -  Wednesday 22 February
Pneumococcal vaccines for elderly adults

The first NCIRS seminar covered the internationally controversial area of pneumococcal vaccines for elderly adults. Persons over 65 have a progressively increasing incidence of pneumococcal invasive disease and pneumonia but both available vaccines have limitations. In Australia the PBAC has recommended, in principle, moving from 23 valent polysaccharide vaccine to 13 valent conjugate vaccine to prevent pneumonia.

Epidemiologists Prof. Robert Booy and Dr Sanjay Jayasinghe presented on the issues on Wednesday 22nd February

Video resources

1. Introduction by Prof. P. McIntyre and Talk 1: Pneumococcal disease epidemiology in the elderly & 13vPCV efficacy by Sanjay Jayasinghe

 

2. Talk 2: Comparing the effectiveness of polysaccharide pneumococcal vaccine in bacteremic and non-bacteremic pneumonia: Focus on pneumococcal pneumonia by Prof. Robert Booy

 

3. Questions & Discussion: Pneumococcal Vaccines for Elderly Adults